Trials / Conditions / Clear Cell Renal Carcinoma

Clear Cell Renal Carcinoma

13 registered clinical trials studyying Clear Cell Renal Carcinoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases NCT07043608	Kelly Fitzgerald, MD	Phase 2
Recruiting	Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma NCT06940518	M.D. Anderson Cancer Center	Phase 2
Unknown	Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors NCT06221774	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Phase 1 / Phase 2
Terminated	Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma NCT04150562	National Cancer Institute (NCI)	Phase 2
Completed	89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE NCT03556046	Radboud University Medical Center	Phase 1
Completed	Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Trea NCT03066427	Spanish Oncology Genito-Urinary Group	Phase 2
Completed	Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project NCT02685553	Universita di Verona	Phase 1
Completed	Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma: NCT02348008	Arkadiusz Z. Dudek, MD	Phase 1 / Phase 2
Completed	Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Ev NCT01715935	Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie	Phase 2
Terminated	Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients NCT01599754	SFJ Pharma Ltd. II	Phase 3
Completed	AMG 172 First in Human Study in Patients With Kidney Cancer NCT01497821	Amgen	Phase 1
Completed	Rotating Pazopanib and Everolimus to Avoid Resistance NCT01408004	Netherlands Working Group on Immunotherapy of Oncology	Phase 2
Completed	TroVax Renal Immunotherapy Survival Trial NCT00397345	Oxford BioMedica	Phase 3